068270.KS Earnings — Celltrion, Inc.
KSC
Updated
When is 068270.KS's next earnings date?
Celltrion, Inc. (068270.KS) has not announced its next earnings date yet. Its most recent earnings report was on Tuesday, October 27, 2026.
How did 068270.KS do in its last earnings report?
In its most recent report on Oct 27, 2026, Celltrion, Inc. posted EPS of $324.82 versus the $1653.73 estimate, a miss. Revenue was $1.58T against a $1.46T estimate.
How much does 068270.KS stock move after earnings?
068270.KS beat EPS estimates in 1 of its last 3 reported quarters.
About Celltrion, Inc.
Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the development and manufacturing of protein-based therapies, including treatments for oncology. Its commercial portfolio features established products such as Remsima, Truxima, and Herzuma, alongside a range of generic pharmaceuticals and diagnostic kits for COVID-19. The company maintains an extensive pipeline of antibody biosimilars currently undergoing various stages of clinical evaluation. Late-stage (Phase 3) candidates include CT-P17, aimed at rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease (IBD); CT-P16, targeting metastatic colorectal and breast cancers; CT-P43, for inflammatory conditions like psoriasis, Crohn's disease, and ulcerative colitis; CT-P42, addressing diabetic macular edema; and CT-P59, developed for COVID-19. In Phase 2, CT-P27 is being tested for pandemic and seasonal influenza. Earlier in development, Phase 1 assets comprise CT-P39 for asthma and urticaria, CT-P41 for osteoporosis and bone loss, and CT-G20 for cardiomyopathy. Additionally, Celltrion maintains a collaboration with Inhalon Biopharma, Inc. to advance IN-006, an inhaled formulation of regdanvimab intended for the treatment of COVID-19 patients. Established in 2002, the company operates primarily from its headquarters in Incheon, South Korea.
🤖 AI Earnings Analysis
068270.KS trades at 33× earnings with a strong 24.8% profit margin; no recent news or guidance data was provided to assess catalysts.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-27 | 1653.73 | 324.82 | — | $1575.50B | ❌ Miss | — | — | — | |
| 2026-10-12 | 1653.73 | 1689.92 | — | $1499.90B | ✅ Beat | — | — | — | |
| 2026-07-26 | 1622.68 | 1554.23 | — | $1393.70B | ❌ Miss | — | — | — |
Showing last 3 quarters.